Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23 2021, the Food and Drug Administration granted accelerated...
Loncastuximab tesirine is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma who have undergone two or more prior lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. The above indication is approved under...
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Miami Cancer Institute, Miami, Florida, United States
Memorial Cancer Institute - Memorial Hospital West, Pembroke Pines, Florida, United States
Account University College London Hospitals NHS Foundation Trust, London, United Kingdom
Hospital Universitario La Paz, Madrid, Spain
Hospital Universitario Virgen del RocÃo, Sevilla, Spain
University of California San Diego Moores Cancer Center, La Jolla, California, United States
Redlands Community Hospital, Redlands, California, United States
The Oncology Institute of Hope and Innovation, Whittier, California, United States
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
The Christie NHS Foundation Trust, Manchester, United Kingdom
Centre Hospitalier Lyon Sud, Pierre-Bénite, France
U.O. Oncologia ed Ematologia, Rozzano, Milano, Italy
Divisione di Oncoematologia, Milano, Italy
NHS Greater Glasgow and Clyde, Glasgow, Scotland, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.